ATAI

ATAI Life Sciences BV

Price

$7.36

return (12m)

85.39%

p/e

-3.92

p/bv

14.85

DIVIDEND YIELD

0.00%

ATAI price

ATAI Life Sciences BV

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment ATAI

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

2.22%

3 months

69.98%

1 year

85.39%

2 years

461.83%

5 years

0.00%

10 years

0.00%

Asset Comparator

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Fundamentals ATAI

Valuation

P/E

-3.92

Sector 7.79

Industry 7.79

P/BV

14.85

Sector 2.11

Industry 2.11

P/Revenue (PSR)

586.28

Sector 2.22

Industry 2.22

EV/EBITDA

-74.21

Sector -156.98

Industry -156.98

EV/EBIT

-73.73

Sector -1,355,776,171.42

Industry -1,355,776,171.42

P/EBITDA

-3.93

Sector 2.51

Industry 2.51

P/EBIT

-3.92

Sector 0.34

Industry 0.34

P/Total Assets

9.90

Sector 1.00

Industry 1.00

P/Net Current Assets

16.76

Sector -3.84

Industry -3.84

P/Working Capital

12.12

Sector -5,077.26

Industry -5,077.26

EPS

-1.85

Sector 0.67

Industry 0.67

BVPS

0.49

Sector 10.17

Industry 10.17

Efficiency

Gross Margin

100.00%

Sector 32.61%

Industry 32.61%

EBITDA Margin

-1,898.24%

Sector -284.80%

Industry -284.80%

EBIT Margin

-1,910.59%

Sector -4.02%

Industry -4.02%

Operating Margin

-100.00%

Sector 4.45%

Industry 4.45%

Net Profit Margins

-100.00%

Sector 2.39%

Industry 2.39%

Asset Turnover

0.01

Sector 0.11

Industry 0.11

Profitability

ROE

-378.70%

Sector 2.05%

Industry 2.05%

ROA

-252.34%

Sector -0.90%

Industry -0.90%

ROIC

-772.13%

Sector -118.95%

Industry -118.95%

Dividends

Dividend yield

0.00%

Sector 0.60%

Industry 0.60%

Payout

Sector 11.53%

Industry 11.53%

Debt

Current Ratio

8.58

Sector 1.44

Industry 1.44

Net Debt / EBITDA

7.00

Sector -39,522,158.34

Industry -39,522,158.34

Net Debt / EBIT

6.95

Sector -31.03

Industry -31.03

Net Debt / Equity

-1.28

Sector -0.72

Industry -0.72

Gross Debt / Equity

0.00

Sector 0.21

Industry 0.21

Equity/Assets

0.67

Sector 0.43

Industry 0.43

Liabilities/Assets

0.33

Sector 0.52

Industry 0.52

Growth

5Y Revenue CAGR

-26.17%

Sector -

Industry -

5Y Earnings CAGR

31.83%

Sector -

Industry -

Fundamentals ATAI

DRAG THE FRAME TO SEE MORE DATA

ATAI Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT ATAI Life Sciences BV

ATAI Life Sciences BV

Average Investor10 user rating

4.0 (3 people)

United States

- year

Founded:

Time since IPO - - year

-

Employees

ATAI Life Sciences N.V. (ATAI) is a biotechnology company focused on developing novel therapies for mental health disorders, with an emphasis on psychedelic-based treatments and next-generation compounds.

The company operates through a decentralized model, supporting multiple clinical programs via subsidiaries and strategic partnerships.

Its main activities include:

• Research and development of treatments for depression, anxiety and other mental health conditions.
• Clinical trials across multiple regulatory stages.
• Investments in biotech platforms and early-stage companies.
• Partnerships with research institutions and pharmaceutical firms.

ATAI operates globally, with activities across Europe and the United States, targeting areas of high unmet medical need.

Its performance is influenced by clinical trial outcomes, regulatory approvals, scientific advancements and biotech funding conditions.

ATAI Life Sciences N.V. trades on the Nasdaq under the ticker ATAI.

History and Development

ATAI Life Sciences N.V. was founded in 2018 to accelerate the development of innovative mental health treatments.

Since its inception, the company has built a diversified pipeline of clinical programs focused on disruptive therapeutic approaches.

ATAI went public in 2021 on the Nasdaq, expanding its access to capital and supporting research growth.

In recent years, the company has advanced clinical trials and strengthened strategic partnerships, positioning itself within the emerging mental health biotech space.

Additional Information

ATAI Life Sciences BV (United States) is listed on the Nasdaq and has a market capitalization of $2.62 billion, with shareholders equity totaling $176.44 million.

The Company is listed on the [MARKET_NAME]

Over the past 12 months, ATAI Life Sciences BV reported $4.47 million in revenue, generating net income of $-668.18 million.

Key financial metrics include a P/E ratio of -3.92, a price-to-book (P/B) ratio of 14.85, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker ATAI.

Market cap

$2.62 billion

Net worth

$176.44 million

$176,440,000.00

Assets

$264.79 million

$264,790,000.00

Total Shares Outstanding

361.00 million

361,000,000

Average Daily Trading Volume

$13.34 million

$13,336,216.40

Sector

Others

Industry

Others

ATAI

ATAI revenue and profits

Financial Results ATAI

DRAG THE FRAME TO SEE MORE DATA

ATAI cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

UNH - UnitedHealth Group Incorporated

$388.61 33,84% (12M)

P/E

25.58

2.23%

ROE

13.33%

P/BV

3.41

SHEL - Shell PLC ADR

$92.77 34,82% (12M)

P/E

9.65

3.30%

ROE

14.29%

P/BV

1.38

STLA - Stellantis NV

$5.43 --44,42% (12M)

P/E

-0.61

0.00%

ROE

-35.93%

P/BV

0.22

COR - Cencora Inc.

$317.10 5,40% (12M)

P/E

22.86

0.76%

ROE

81.04%

P/BV

18.52

SSNLF - Samsung Electronics Co Ltd

$- -0,00% (12M)

P/E

13.54

4.85%

ROE

1.69%

P/BV

0.23

ALIZY - Allianz SE ADR

$51.08 --13,60% (12M)

P/E

14.12

2.66%

ROE

17.89%

P/BV

2.53

TTE - TotalEnergies SE ADR

$90.07 54,62% (12M)

P/E

7.06

4.61%

ROE

21.42%

P/BV

1.51

NSRGY - Nestle SA ADR

$99.21 9,18% (12M)

P/E

11.98

4.01%

ROE

58.05%

P/BV

6.96